Eurofins Scientific services

Global coverage; By utilizing our wholly-owned harmonized laboratory facilities in the United States, Europe, Singapore and China, Eurofins Central Laboratory is able to accomodate clinical trials of any nature, size, foot print or complexity. Especially with the increasing number of study protocols that involve a variety in esoteric testing like therapeutic drug monitoring, it is of pivotal importance to use globally standardized laboratory facilities that are situated close to the patients. The global footprint of Eurofins Central Laboratory ensures specimen integrity, optimal turn around times of results and manageability of the logistic processes and associated costs.

Eurofins Genomics offers comprehensive genetic analysis of sample groups. Both single samples as well as batches of several thousand samples can be processed. For example, we offer genotyping for clinical trials according to the Good Laboratory Practice, GLP (OECD Guideline No.1 on the Principles of Good Laboratory Practice (ENV/MC/CHEM(98)17) and in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, GCP (CPMP/ICH/135/95).

Complete preclinical service: Early and full drug development is regulatory-driven and complex. The priority in this selection process is to achieve the safety and efficacy of a new molecular entity. The preclinical activity includes mainly safety and pharmacological testing accompanied by metabolism, bioanalysis, biomarker development and pharmaceutical analysis. Eurofins offers the whole panel of GLP-assured safety studies and a broad range of pharmacological models including complementary activities such as ADME analysis. As preclinical activity is conducted throughout all phases of drug development, it needs to be well integrated in the regulatory-driven drug development strategy. Our clients benefit from our expertise in consultancy together with our flexibility and scientific excellence to test their compounds.